Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c
Journal
Journal of Internal Medicine of Taiwan
Journal Volume
29
Journal Issue
6
Pages
364-373
Date Issued
2018
Author(s)
Abstract
Chronic hepatitis C is one of the main reasons for the high ranking of liver diseases in Taiwan. With the popularization of oral direct-acting antiviral drugs (DAA), DAAs have been reimbursed by the NHI, and achieved per- protocol SVR rate up to 97%. Despite good SVR rate, less than 10% of the entire hepatitis C population in Taiwan are willing to seek treatment, so there is still a great unmet need in prevention of hepatitis C. Under limited resources, we suggest a pilot project by expanding screening and treatment universalization with DAA and expect to eradicate hepatitis C in Taiwan as soon as possible. (J Intern Med Taiwan 2018; 29:364-373).
SDGs
Publisher
Society of Internal Medicine of Taiwan
Type
journal article